Vandetanib Shows Potential in Preventing Hantavirus-Induced Vascular Leakage Through VEGFR2 Inhibition
Nikhil Prasad Fact checked by:Thailand Medical News Team May 14, 2026 1 hour, 2 minutes ago
Medical News: Hantaviruses represent a significant global health threat, causing two severe syndromes: hemorrhagic fever with renal syndrome (HFRS) in Asia and Europe, and hantavirus pulmonary syndrome (HPS or HCPS) in the Americas.
Vandetanib, a Tyrosine-Kinase Inhibitor Targeting VEGFR2 Shows Promise in Reducing Vascular Permeability
Caused by Hantavirus
These rodent-borne pathogens infect endothelial cells without causing direct cell lysis, yet they trigger profound increases in vascular permeability. This leakage leads to life-threatening complications such as hypotension, pulmonary edema, and multi-organ failure.
Current treatments remain supportive, with no approved antiviral therapies or vaccines widely available, underscoring the urgent need for innovative interventions. Recent preclinical research has spotlighted repurposed drugs like Vandetanib, a multi-tyrosine kinase inhibitor primarily approved for advanced medullary thyroid cancer, as a potential modulator of this vascular dysfunction.
Understanding Hantavirus-Induced Vascular Leakage
Hantavirus pathogenesis centers on the disruption of endothelial barrier integrity. Pathogenic strains, including Andes virus (ANDV) and Hantaan virus (HTNV), sensitize human endothelial cells to vascular endothelial growth factor (VEGF).
This sensitization occurs through the dissociation of β3 integrin from VEGFR2 (vascular endothelial growth factor receptor 2), leading to hyperphosphorylation of VEGFR2. The result is activation of downstream signaling pathways, particularly Src family kinases (SFKs), which promote the internalization and degradation of VE-cadherin—a critical protein maintaining adherens junctions between endothelial cells.
Elevated VEGF levels in patient plasma correlate with disease severity, amplifying permeability and capillary leakage. In HPS, this manifests as non-cardiogenic pulmonary edema; in HFRS, it drives renal and hemorrhagic complications. Studies have long established that hantaviruses do not damage cells directly but hijack host signaling to weaken vascular barriers, making receptor-targeted therapies a logical avenue for intervention.
VEGFR2 as a Therapeutic Target in Hantavirus Infection
VEGFR2 stands out as a central player in this process. By blocking its activation, researchers hypothesized that downstream VE-cadherin loss could be prevented, stabilizing endothelial monolayers. Earlier work demonstrated that small-molecule inhibitors of VEGFR2 and SFKs could suppress ANDV-induced permeability in vitro. For instance, inhibitors like pazopanib and dasatinib blocked VE-cadherin dissociation by over 90% in infected human umbilical vein endothelial cells (HUVECs), highlighting the pathway's druggability.
These findings paved the way for evaluating clinically approved VEGFR2 antagonists, shifting focus from broad antivirals to host-directed therapies that preserve vascular function even in the presence of viral infection.
Vandetanib’s Mechanism: Precision Inhibition of VEGFR2 Signaling
Vandetanib (also known as
ZD6474) is an orally active tyrosine kinase inhibitor that potently targets VEGFR2, along with EGFR and RET kinases. In the context of hantavirus, its primary benefit derives from VEGFR2 blockade. By preventing receptor phosphorylation, Vandetanib interrupts the VEGF hypersensitivity induced by the virus, thereby reducing VE-cadherin degradation and maintaining endothelial tight junctions. In vitro experiments confirmed that Vandetanib inhibits VEGFR2 phosphorylation and limits permeability changes in ANDV-infected endothelial models, offering a targeted counter to the virus’s pathogenic strategy.
Importantly, this approach does not aim to kill the virus directly but to mitigate the host’s exaggerated response, potentially buying critical time for immune clearance and supportive care.
Preclinical Promise in Hamster Models of HPS
The most compelling evidence comes from animal studies using the Syrian hamster model, which closely recapitulates human HPS caused by ANDV. In a 2016 study led by researchers at the Centers for Disease Control and Prevention, prophylactic administration of Vandetanib significantly altered disease progression. Hamsters received daily oral doses of 10, 25, or 50 mg/kg starting five days before ANDV challenge. Treatment delayed the onset of lethal disease and boosted overall survival by 23% compared to untreated controls.
This modest but meaningful improvement underscores Vandetanib’s ability to temper vascular leakage without eradicating the virus. However, the same regimen showed no protective effect when initiated after viremia onset, suggesting a narrow therapeutic window limited to pre- or early post-exposure scenarios. Complementary in vitro data reinforced these results, showing reduced endothelial permeability through stabilized VE-cadherin.
Challenges and Considerations for Clinical Translation
While promising, Vandetanib’s repurposing faces hurdles. As an anticancer agent, it carries known side effects including hypertension, dermatologic reactions (such as rash), diarrhea, and potential cardiorespiratory issues—complications that could complicate its use in acutely ill hantavirus patients. Timing remains critical; post-exposure efficacy appears limited, raising questions about real-world deployment in outbreak settings or endemic areas. Moreover, hantavirus infections are often diagnosed late, after vascular symptoms emerge.
Future research must explore combination therapies—pairing Vandetanib with antivirals, monoclonal antibodies, or bradykinin antagonists—to broaden the window of efficacy. Human trials are needed to validate safety and dosing in infected individuals, alongside pharmacokinetic studies tailored to hantavirus pathophysiology. Regional relevance is high for Asia, where HFRS strains circulate, and global travel increases HPS importation risks.
This
Medical News report emphasizes that Vandetanib represents a host-targeted strategy distinct from traditional antivirals, offering hope for a condition where options are scarce. By addressing the core driver of morbidity—vascular permeability—it could complement supportive care and reduce mortality in severe cases.
Broader Implications for Emerging Infectious Diseases
The success of VEGFR2 inhibition in preclinical hantavirus models highlights a paradigm shift toward drug repurposing for neglected tropical and zoonotic threats. With climate change expanding rodent reservoirs and human encroachment increasing spillover events, such therapies could prove versatile against other permeability-driven viral hemorrhagic fevers. Ongoing surveillance and collaborative research will determine whether Vandetanib advances from bench to bedside, potentially transforming outcomes for patients facing these deadly infections.
In summary, while not a cure, Vandetanib’s targeted action against VEGFR2 demonstrates clear preclinical promise in mitigating hantavirus-induced vascular damage. Continued investigation could position it as a valuable addition to the limited arsenal against hantaviral diseases.
References:
https://www.sciencedirect.com/science/article/abs/pii/S0166354216301140
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1233433/full
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.02989/full
https://journals.asm.org/doi/10.1128/jvi.02319-10
https://journals.asm.org/doi/10.1128/jvi.02397-07
https://www.mdpi.com/1999-4915/11/7/610
For the latest on hantavirus, keep on logging to Thailand
Medical News
Read Also:
https://www.thailandmedical.news/articles/hantavirus-news
Share
Tweet
Share
